Upadacitinib is an oral targeted medicine that calms an overactive immune system by blocking specific signalling pathways inside immune cells. It belongs to a class of medicines called JAK (Janus kinase) inhibitors, used across several inflammatory and autoimmune conditions including rheumatoid arthritis and atopic dermatitis. It is a prescription-only medicine that carries a boxed warning.

• Therapeutic Class: Targeted immunomodulator for autoimmune/inflammatory conditions.

• Pharmacological Class: Janus kinase (JAK) inhibitor, selective for JAK1.

• Drug Family: Small-molecule JAK inhibitors.

• ATC Classification: L04AA44 (Upadacitinib).

Approved: Moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, giant cell arteritis, refractory moderate to severe atopic dermatitis, ulcerative colitis, Crohn's disease, and polyarticular juvenile idiopathic arthritis/juvenile psoriatic arthritis — generally after an inadequate response to one or more TNF blockers where specified.

Commonly used for: Adults (and in some indications, adolescents/children) with inflammatory or autoimmune conditions that haven't responded well enough to first-line therapies like TNF blockers.

Off-label use (only under medical guidance): Being studied in other autoimmune/inflammatory conditions in clinical trials; use outside approved indications is a specialist decision.

●       Extended-release oral tablets: 15 mg, 30 mg, and 45 mg.

●       Oral solution (RINVOQ LQ): for patients unable to swallow tablets, including younger pediatric patients.

Upadacitinib blocks an enzyme called Janus kinase 1 (JAK1), which immune cells use to relay signals from inflammatory messengers (cytokines) that drive conditions like rheumatoid arthritis and atopic dermatitis. By blocking this signalling pathway, upadacitinib reduces the inflammatory activity that damages joints, skin, or the gut, depending on the condition being treated.

• Standard dose (RA, PsA, AS, nr-axSpA): 15 mg once daily.

• Condition-wise dose: Dosing varies by indication — for example, atopic dermatitis and ulcerative colitis/Crohn's disease may use different starting or maintenance doses (commonly 15 mg or 30 mg once daily, with induction dosing higher in some gastrointestinal indications) as determined by the treating specialist.

• Route: Oral, swallowed whole, with or without food; tablets should not be split, crushed, or chewed.

• Missed dose: Take as soon as remembered on the same day; don't double up.

• Overdose: May increase the risk of infection or other known side effects; requires medical attention.

• Common: Upper respiratory tract infections, nausea, headache, and elevated cholesterol levels.

• Serious: Serious infections (including tuberculosis reactivation), decreases in blood counts (neutropenia, lymphopenia, anaemia), and elevated liver enzymes.

• Emergency symptoms: Signs of serious infection (fever, chills, persistent cough), chest pain, sudden weakness or slurred speech (possible stroke), leg swelling or pain (possible blood clot), or unusual bleeding or bruising.

• Recovery advice: Because upadacitinib affects the immune system, prompt reporting of any new infection symptoms is important; scheduled blood tests allow early detection of blood count or liver enzyme changes.

• Pregnancy: Not recommended; may cause fetal harm.

• Breastfeeding: Not recommended during treatment.

• Liver disease: Used with caution; liver enzymes are monitored during treatment.

• Kidney disease: Dose adjustment may be needed in significant impairment.

• Elderly: Used with particular caution in patients 50 and older with cardiovascular risk factors, given the boxed warning.

• Children: Approved for certain indications (e.g., atopic dermatitis, polyarticular juvenile idiopathic arthritis) from age 12 or younger depending on the specific condition and formulation.

●       Other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine, cyclosporine): not recommended in combination, due to increased risk of excessive immunosuppression.

●       Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase upadacitinib levels; dose adjustment may be needed.

●       Strong CYP3A4 inducers (e.g., rifampin): can significantly reduce upadacitinib's effectiveness.

●       Live vaccines: should be avoided during treatment; vaccinations should be brought up to date before starting.

●       Complete blood counts (neutrophils, lymphocytes, hemoglobin) before and during treatment.

●       Liver function tests periodically.

●       Lipid profile, given associated cholesterol increases.

●       Screening for tuberculosis and viral hepatitis before starting; ongoing monitoring for infection signs throughout treatment.

Tofacitinib, Baricitinib (other JAK inhibitors); Adalimumab, Etanercept (TNF blockers, different mechanism, often used before JAK inhibitors).

Often used alongside methotrexate in rheumatoid arthritis, though it can also be used as monotherapy; not combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants.

●       Rheumatoid Arthritis Medicines

●       Atopic Dermatitis Treatments

●       Inflammatory Bowel Disease Medicines

●       JAK Inhibitors

1. Eat These 9 Foods For Rheumatoid Arthritis

2. Difference Between Osteoarthritis And Rheumatoid Arthritis

3. https://www.mrmed.in/health-library/immune-disorders/rheumatoid-arthritis

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s015lbl.pdf

2. https://www.rinvoqhcp.com/rheumatology/safety

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.